Brokerages Set Omeros Corporation (NASDAQ:OMER) Target Price at $33.67

Shares of Omeros Corporation (NASDAQ:OMER) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $33.6667.

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Omeros in a report on Wednesday, October 8th. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Wednesday, December 24th. Wall Street Zen upgraded shares of Omeros from a “sell” rating to a “hold” rating in a report on Saturday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. Finally, WBB Securities restated a “strong-buy” rating and set a $45.00 target price on shares of Omeros in a report on Wednesday, October 15th.

Institutional Trading of Omeros

Large investors have recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Omeros by 11.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 29,097 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 2,941 shares during the period. Harbour Investments Inc. grew its holdings in shares of Omeros by 46.1% in the second quarter. Harbour Investments Inc. now owns 13,469 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 4,251 shares during the period. Russell Investments Group Ltd. increased its position in Omeros by 113.1% during the third quarter. Russell Investments Group Ltd. now owns 10,695 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 5,677 shares during the last quarter. Rhumbline Advisers raised its stake in Omeros by 7.1% during the third quarter. Rhumbline Advisers now owns 105,873 shares of the biopharmaceutical company’s stock worth $434,000 after purchasing an additional 7,048 shares during the period. Finally, Cypress Capital Group raised its stake in Omeros by 20.7% during the second quarter. Cypress Capital Group now owns 42,000 shares of the biopharmaceutical company’s stock worth $126,000 after purchasing an additional 7,200 shares during the period. 48.79% of the stock is currently owned by hedge funds and other institutional investors.

Omeros Price Performance

NASDAQ OMER opened at $16.38 on Friday. The stock’s 50 day simple moving average is $9.97 and its 200-day simple moving average is $6.31. The company has a market cap of $1.16 billion, a PE ratio of -8.11 and a beta of 2.38. Omeros has a 1-year low of $2.95 and a 1-year high of $17.65.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.58) by $0.39. On average, equities research analysts anticipate that Omeros will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.